14 Best Undervalued Stocks to Buy Under $50

2. Bristol-Myers Squibb Company (NYSE:BMY)

Stock Price: $46.63

​Forward P/E: 7.12

Number of Hedge Fund Holders: 67

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best undervalued stocks to buy under $50. Bristol-Myers Squibb Company (NYSE:BMY) was assigned a Hold rating by Bernstein analyst Courtney Breen on November 3, who maintained the price target at $58.

Bristol-Myers Squibb Company (NYSE:BMY) announced strong Q3 results on October 30, with both revenue and EPS exceeding expectations, supported by pipeline advancements, growth portfolio momentum, and strategic business development.

Growth portfolio revenues rose 18% to $6.9 billion compared to the prior year period, driven primarily by the company’s immuno-oncology (IO) portfolio, Reblozyl, Camzyos and Breyanzi. However, revenues of the Legacy Portfolio dropped 12% to $5.4 billion, because of expected continued generic impact across the rest of the Legacy Portfolio more than offsetting the increased demand for Eliquis. GAAP EPS for the quarter was $1.08 and non-GAAP EPS was $1.63.

Bristol-Myers Squibb Company (NYSE:BMY) also raised its full-year 2025 non-GAAP revenue guidance to an approximately $47.5 billion to $48.0 billion range from the previous range of around $46.5 billion to $47.5 billion, with the update taking into account the continued solid performance of the company’s Growth Portfolio.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.